Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MBRX
stocks logo

MBRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2026Q1
--
--
-0.263
-90.76%
--
--
-0.450
-34.78%
Estimates Revision
The market is revising No Change the revenue expectations for Moleculin Biotech, Inc. (MBRX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -17.76%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-17.76%
In Past 3 Month
Wall Street analysts forecast MBRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBRX is 6.67 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast MBRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBRX is 6.67 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.710
sliders
Low
4.00
Averages
6.67
High
12.00
Current: 7.710
sliders
Low
4.00
Averages
6.67
High
12.00
Roth Capital
Jonathan Aschoff
Buy
downgrade
$20 -> $13
2025-06-27
Reason
Roth Capital
Jonathan Aschoff
Price Target
$20 -> $13
2025-06-27
downgrade
Buy
Reason
Roth Capital analyst Jonathan Aschoff lowered the firm's price target on Moleculin Biotech to $13 from $20 and keeps a Buy rating on the shares following the recent capital raise. The firm cites financial model adjustments for the target cut. Roth believes Moleculin's warrant exercise should be able to fund operations to the end of 2025, given the MIRACLE trial unblinded initial interim data announcement from 45 patients that it expects in the second half of 2025.
H.C. Wainwright
H.C. Wainwright
initiated
$4
2025-06-09
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$4
2025-06-09
initiated
Reason
H.C. Wainwright assumed coverage of Moleculin Biotech with a Buy rating and $4 price target. Moleculin is a clinical-stage biotech company advancing treatments for highly resistant cancers and viruses, the analyst tells investors in a research note. The firm says the MIRACLE Part A data could position annamycin for accelerated approval in second-line acute myeloid leukemia.
Maxim Group
Jason McCarthy
Hold
to
Strong Buy
Upgrades
$4
2025-03-25
Reason
Maxim Group
Jason McCarthy
Price Target
$4
2025-03-25
Upgrades
Hold
to
Strong Buy
Reason
Maxim analyst Jason McCarthy upgraded Moleculin Biotech to Buy from Hold with a $4 price target.
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$8
2025-03-25
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$8
2025-03-25
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$8
2025-03-24
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$8
2025-03-24
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Maintains
$8
2025-03-03
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$8
2025-03-03
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Moleculin Biotech Inc (MBRX.O) is -0.20, compared to its 5-year average forward P/E of -1.57. For a more detailed relative valuation and DCF analysis to assess Moleculin Biotech Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.57
Current PE
-0.20
Overvalued PE
0.12
Undervalued PE
-3.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.04
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.27
Undervalued EV/EBITDA
-0.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MBRX News & Events

Events Timeline

(ET)
2025-11-26
09:02:00
Moleculin Biotech declares a 1-for-25 reverse stock split.
select
2025-11-13 (ET)
2025-11-13
08:40:32
Moleculin Biotech announces that 60% of the initial 45 participants have been enrolled in the 'MIRCALE' Phase 3 trial.
select
2025-11-12 (ET)
2025-11-12
08:43:13
Moleculin Biotech Reveals Research Funded by Grant to Assess Annamycin
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-28NASDAQ.COM
Moleculin Biotech to Showcase Company Overview in Virtual Investor Closing Bell Series

  • Company Participation: Moleculin Biotech Inc. will participate in the Virtual Investor Closing Bell Series on December 2, 2025, where CEO Walter Klemp will present a corporate overview and engage in a live Q&A session with investors.

  • Lead Program Overview: The company's lead program, Annamycin, is a next-generation anthracycline currently in a pivotal Phase 3 trial for relapsed or refractory acute myeloid leukemia and is also being developed for advanced soft tissue sarcoma.

  • Pipeline Development: Moleculin is advancing several candidates, including WP1066 for glioblastoma and pancreatic cancer, WP1122 for pathogenic viruses and certain cancers, and WP1220 for cutaneous T-cell lymphoma.

  • Stock Performance: As of the latest update, MBRX shares are trading at $0.27, down 1.78%, with a trading range over the past year between $0.25 and $3.65.

[object Object]
Preview
1.0
11-26Newsfilter
Moleculin Biotech CEO to Host Investor Webcast on December 2, 2025
  • Investor Engagement: Moleculin Biotech CEO Walter Klemp will participate in the Virtual Investor Closing Bell Series on December 2, 2025, at 4 PM ET, providing a corporate overview and business outlook aimed at enhancing investor confidence in the company's future developments.
  • Interactive Q&A Session: During the event, participants will have the opportunity to submit questions live, with Klemp aiming to answer as many as possible, fostering interaction with investors and enhancing transparency and trust.
  • Clinical Advancement: Moleculin is advancing its lead program Annamycin into a Phase 3 clinical trial targeting relapsed or refractory acute myeloid leukemia (AML), which could potentially lead to market approval and enhance its competitive position in the biopharmaceutical sector.
  • New Drug Development: The company is also developing immune modulators like WP1066 targeting brain tumors and pancreatic cancer, showcasing Moleculin's broad pipeline in innovative drug development that may lay the groundwork for future revenue growth.
[object Object]
Preview
8.5
11-26Newsfilter
Moleculin Biotech Announces 1-for-25 Reverse Stock Split, Reducing Outstanding Shares to 2.1 Million
  • Reverse Stock Split Implementation: Moleculin Biotech announced a 1-for-25 reverse stock split effective December 1, 2025, reducing outstanding shares from approximately 51.7 million to about 2.1 million, aimed at increasing share price to meet Nasdaq listing requirements.
  • Trading Impact: Post-split, Moleculin's common stock will open on the Nasdaq Capital Market under the new CUSIP number 60855D 408, and while facing challenges from reduced share circulation, the company hopes to enhance its market image through this action.
  • Shareholder Rights Adjustment: The reverse stock split will not issue any fractional shares, and shareholders entitled to fractional shares will receive cash compensation, a measure intended to protect shareholder rights and simplify the shareholder structure.
  • Increased Financing Needs: Moleculin anticipates requiring significant additional financing to support its clinical trials; while the reverse split may help boost share price, the company still faces uncertainties in securing funding to advance its drug development plans.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Moleculin Biotech Inc (MBRX) stock price today?

The current price of MBRX is 7.71 USD — it has increased 1.58 % in the last trading day.

arrow icon

What is Moleculin Biotech Inc (MBRX)'s business?

Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).

arrow icon

What is the price predicton of MBRX Stock?

Wall Street analysts forecast MBRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBRX is 6.67 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Moleculin Biotech Inc (MBRX)'s revenue for the last quarter?

Moleculin Biotech Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Moleculin Biotech Inc (MBRX)'s earnings per share (EPS) for the last quarter?

Moleculin Biotech Inc. EPS for the last quarter amounts to -0.68 USD, decreased -76.14 % YoY.

arrow icon

What changes have occurred in the market's expectations for Moleculin Biotech Inc (MBRX)'s fundamentals?

The market is revising No Change the revenue expectations for Moleculin Biotech, Inc. (MBRX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -17.76%.
arrow icon

How many employees does Moleculin Biotech Inc (MBRX). have?

Moleculin Biotech Inc (MBRX) has 17 emplpoyees as of December 05 2025.

arrow icon

What is Moleculin Biotech Inc (MBRX) market cap?

Today MBRX has the market capitalization of 15.91M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free